Skip to main content

Table 1 In vitro and in vivo selection of de novo primarily elvitegravir-associated resistance substitutions in HIV IN in tissue culture and in INSTI-naïve individuals

From: HIV drug resistance against strand transfer integrase inhibitors

Substitutions

RAL

EVG

DTG

Selection

In vitro

In vivo

In vitro

In vivo

In vitro

In vivo

T66

T66A

X

X

X

X

  

T66I

  

X

X

  

T66I/V72A/A128T

  

X

   

T66I/E92Q

  

X

   

T66I/E92Q/T124A

  

X

   

T66I/Q95K/E138K/Q146P/S147G

  

X

   

T66I/T97A/G163R

X

     

T66I/T124A

  

X

   

T66I/T124A/Q146L

  

X

   

T66I/I203M

 

X

    

T66I/F121Y/S153Y/D232N

  

X

   

T66I/D232N

  

X

   

T66I/R263K

  

X

   

T66K

X

 

X

X

  

T66K/L74M

X

     

T124A/T66K

X

 

X

   

E92

E92G

  

X

   

E92Q

X

X

X

X

X

 

L74M/E92Q

 

X

    

H51Y/E92Q/S147G

  

X

   

H51Y/E92Q/S147G/E157Q

  

X

   

E92Q/M154I

X

     

E92V

  

X

   

E92V/T124A

  

X

   
  1. ‘X’ marks a report of the selection of a substitution or combination of substitutions. Numbers refer to amino acid position in HIV integrase, one letter amino acid code used
  2. References: [14, 18,19,20, 28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53]